Skip to main content

Mologic, BioSure Partner to Produce SARS-CoV-2 Antibody Self-Test

NEW YORK – Diagnostic firm Mologic and self-test designer BioSure said on Monday that they have partnered to produce a SARS-CoV-2 antibody self-test.

The test will combine Mologic's lateral flow assay with BioSure's self-test design, the companies said. It doesn't require training and offers results in 10 minutes from a drop of blood. The assay is currently undergoing final validations, the companies added.

The BioSure COVID-19 Antibody Self-Test is expected to be ready for mass production at the beginning of June and will be available in the UK and global markets, the companies said. 

Bedfordshire, UK-based Mologic also noted that materials for its diagnostic tests are being supplied to the Institut Pasteur de Dakar in Senegal to manufacture SARS-CoV-2 tests for Africa. Earlier this year, Mologic received £1 million ($1.3 million) from the Wellcome Trust and the Department for International Development to develop a point-of-need SARS-CoV-2 diagnostic test.